Cefotiam therapy of lower respiratory tract infections.

Abstract

Cefotiam, a new cephalosporin, was evaluated in the treatment of lower respiratory tract infections in 29 patients. The bacteria isolated from the sputum of these patients included Streptococcus pneumoniae (31%), Klebsiella pneumoniae (31%), and Haemophilus influenzae (28%). Satisfactory response was observed in 90% of the patients. There were three treatment failures, two superinfections, and four colonizations with gram-negative organisms resistant to the drug. Superficial phlebitis was noted in two patients. The results of this study suggest that cefotiam is an effective and well-tolerated antibiotic for the treatment of lower respiratory tract infections due to susceptible organisms.

• Authors: M A Polis, C U Tuazon
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 28 Issue 4 Pg. 576-7 (Oct 1985) ISSN: 0066-4804 [Print] United States
• PMID: 3865632 (Publication Type: Journal Article)

Chemical References

• Cefotiam
• Cefotaxime

Topics

• Adult
• Aged
• Cefotaxime (analogs & derivatives, therapeutic use)
• Cefotiam
• Female
• Humans
• Male
• Middle Aged
• Respiratory Tract Infections (drug therapy, microbiology)